Azathioprine treatment in multiple sclerosis; pretreatment assessment of metaboliser status
| Autor: | F J Thomas, T A T Hughes, A Anstey |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Drug
Multiple Sclerosis Thiopurine methyltransferase biology business.industry media_common.quotation_subject Multiple sclerosis Azathioprine Cellular level Pharmacology medicine.disease Mercaptopurine Psychiatry and Mental health Immune system In vivo medicine biology.protein Humans Surgery Neurology (clinical) Letters to the Editor business media_common medicine.drug |
| Zdroj: | Journal of Neurology, Neurosurgery & Psychiatry. 70:815-815 |
| ISSN: | 0022-3050 |
| DOI: | 10.1136/jnnp.70.6.815 |
| Popis: | Azathioprine is a cytotoxic immunosuppressant drug used widely in clinical neurology as an adjunct to steroid treatment for autoimmune and inflammatory conditions. As a result of the relatively high cost and modest benefit of the newly licensed immunomodulatory therapies in the treatment of multiple sclerosis there has been a resurgence of interest in the possible benefits of azathioprine. A meta-analysis in 1997 suggested that it was as effective as newer treatments in increasing the proportion of patients who remain free of relapse at 2 years.1 The mode of action of azathioprine at the immune cell level remains unclear. It is converted rapidly in vivo to 6-mercaptopurine, which is extensively metabolised along three competitive routes (table1).2 Methylation catalysed by thiopurine transferase (TPMT) leads to the production of 6-methyl mercaptopurine. … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|